Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 19/20 | 0.88 |
| ▸ | MAPK9 | P45984 | 19/20 | 0.88 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.88 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.72 |
| ▸ | CCNK | O75909 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | CCNH | P51946 | 1/20 | 0.52 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.52 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22106110 | 1.00 | MAPK8 (0.88) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 | |
| SCHEMBL22095484 | 0.94 | MAPK8 (1.00) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 | |
| SCHEMBL22095513 | 0.94 | MAPK8 (1.00) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 | |
| SCHEMBL22095486 | 0.94 | MAPK8 (1.00) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 | |
| SCHEMBL22095697 | 0.93 | MAPK8 (0.76) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 | |
| SCHEMBL22106121 | 0.92 | MAPK8 (0.81) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 | |
| SCHEMBL22095685 | 0.91 | MAPK8 (1.00) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 | |
| SCHEMBL22095687 | 0.91 | MAPK8 (1.00) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 | |
| SCHEMBL22095700 | 0.91 | MAPK8 (1.00) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 | |
| SCHEMBL22095528 | 0.90 | MAPK8 (1.00) | MAPK8MAPK9PIKFYVEMAPK10MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20220073512-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| WO-2020123925-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073512-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | MAP3K3, MAP2K3, MAP3K2 | MAPK8 48/4885MAPK9 38/4885PIKFYVE 1582/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | MAPK8 83/4885MAPK9 107/4885PIKFYVE 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.